Page last updated: 2024-10-26

doxazosin and Insulin Sensitivity

doxazosin has been researched along with Insulin Sensitivity in 18 studies

Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.

Research Excerpts

ExcerptRelevanceReference
"We determined the effect of alpha-adrenergic blocking agent doxazosin on insulin resistance in 19 hypertensive patients (blood pressure [BP] >160/90 mmHg) with obesity (mean body mass index [BMI]: 26."9.10Effect of doxazosin on insulin resistance in hypertensive patients with obesity. ( Miyachi, Y; Ueshiba, H, 2003)
"There are not studies about the utility of modified liberation doxazosin (MLD) in the combined treatment of the true resistant hypertension (TRH)."7.72[Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension]. ( Aliaga Martínez, L; Fernández-Torres, C; Jiménez-Alonso, J; Mediavilla García, JD; Sabio, JM, 2004)
"The fibrinolytic and metabolic changes associated with doxazosin treatment were evaluated in 20 patients with mild to moderate hypertension."7.69Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. ( Huang, SH; Jeng, CY; Jeng, JR; Sheu, WH; Shieh, SM, 1996)
"Insulin resistance (IR) in chronic renal failure (CRF) is well-known."6.70Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. ( Akkaya, V; Celik, AV; Gürol, AO; Hursit, M; Karsidag, K; Kayacan, SM; Yazici, H; Yildiz, A, 2002)
"Doxazosin treatment resulted in a dose-dependent reduction of basal insulin levels in group A to 16 +/- 3 microU/ml; p <0."5.30Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters. ( Beckmann, R; Binder, BR; Christ, G; Gabriel, H; Huber, K; Mundigler, G; Zehetgruber, M, 1998)
"Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy."5.29Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994)
" The dose was titrated individually upwards from 1 mg until the diastolic blood pressure was below 90 mm Hg, side-effects precluded further dosage increase or the maximum daily dose of 16 mg was achieved."5.28Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. ( Huupponen, R; Lehtonen, A; Vähätalo, M, 1992)
"In the present study, 611 treated hypertensive patients with morning hypertension were randomized into either a doxazosin group, for whom a once-daily bedtime dose of doxazosin was added to the current medication regimen, or a control group, who continued their current medication."5.14Adrenergic blockade improved insulin resistance in patients with morning hypertension: the Japan Morning Surge-1 Study. ( Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kabutoya, T; Kario, K; Matsui, Y; Pickering, TG; Shibasaki, S; Shimada, K, 2009)
"We determined the effect of alpha-adrenergic blocking agent doxazosin on insulin resistance in 19 hypertensive patients (blood pressure [BP] >160/90 mmHg) with obesity (mean body mass index [BMI]: 26."5.10Effect of doxazosin on insulin resistance in hypertensive patients with obesity. ( Miyachi, Y; Ueshiba, H, 2003)
"In a previous open study on the metabolic effects of doxazosin in patients with essential hypertension, subgroup analysis indicated that subjects with an accumulation of risk factors for coronary heart disease (high VLDL triglycerides, low HDL cholesterol and high fasting blood glucose) seemed to benefit most from the metabolic actions of doxazosin treatment."5.08Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. ( Andersson, PE; Lithell, H, 1996)
"Doxazosin (tonocardin) treatment was given for 11 weeks to 33 NIDDM patients with concomitant hypertension."5.08[Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus]. ( Lazebnik, LB; Melichenko, SB; Serebrov, AN, 1998)
"There are not studies about the utility of modified liberation doxazosin (MLD) in the combined treatment of the true resistant hypertension (TRH)."3.72[Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension]. ( Aliaga Martínez, L; Fernández-Torres, C; Jiménez-Alonso, J; Mediavilla García, JD; Sabio, JM, 2004)
"To examine the effect of the alpha 1-adrenoblocker tonocardin (doxazosin) on the course of arterial hypertension (AH) and on carbohydrate and lipid metabolism and insulin resistance in patients with type 2 diabetes mellitus (DM) concurrent with AH."3.71[Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension]. ( Balabolkin, MI; Khasanova, ER; Kreminskaia, VM; Trukhina, TV, 2002)
" With the monotherapy of essential hypertension concurrent with hypercholesterolemia with the alpha 1-adrenoblocker Doxazosin, in addition to the agent's high antihypertensive effects, the authors noted its favourable action on lipid spectral parameters and platelet functional activity."3.69[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment]. ( Ivleva, AIa; Kobalava, ZhD; Moiseev, VS, 1995)
"The fibrinolytic and metabolic changes associated with doxazosin treatment were evaluated in 20 patients with mild to moderate hypertension."3.69Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. ( Huang, SH; Jeng, CY; Jeng, JR; Sheu, WH; Shieh, SM, 1996)
"Insulin resistance was measured by homeostasis assessment index (HOMA)."2.73Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. ( Acikel, C; Caglar, K; Celik, T; Eyileten, T; Oguz, Y; Sonmez, A; Vural, A; Yavuz, I; Yenicesu, M; Yilmaz, MI, 2007)
"Doxazosin has a neutral effect on both peripheral and hepatic insulin action, but improves endothelium-dependent vasodilation."2.71Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. ( Atkinson, AB; Bassett, J; Bell, PM; Courtney, CH; Ennis, CN; McCance, DR; Sheridan, B, 2003)
"Insulin resistance (IR) in chronic renal failure (CRF) is well-known."2.70Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. ( Akkaya, V; Celik, AV; Gürol, AO; Hursit, M; Karsidag, K; Kayacan, SM; Yazici, H; Yildiz, A, 2002)
"Doxazosin (2 to 4 mg) was administered alone or with other previously received antihypertensive drugs for 6 months."1.31Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. ( Adachi, M; Hirano, T; Kashiwazaki, K; Yoshino, G, 2001)
"Doxazosin treatment resulted in a dose-dependent reduction of basal insulin levels in group A to 16 +/- 3 microU/ml; p <0."1.30Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters. ( Beckmann, R; Binder, BR; Christ, G; Gabriel, H; Huber, K; Mundigler, G; Zehetgruber, M, 1998)
"Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy."1.29Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994)
" The dose was titrated individually upwards from 1 mg until the diastolic blood pressure was below 90 mm Hg, side-effects precluded further dosage increase or the maximum daily dose of 16 mg was achieved."1.28Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. ( Huupponen, R; Lehtonen, A; Vähätalo, M, 1992)

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's8 (44.44)18.2507
2000's9 (50.00)29.6817
2010's1 (5.56)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shibasaki, S1
Eguchi, K1
Matsui, Y1
Ishikawa, J1
Hoshide, S1
Ishikawa, S1
Kabutoya, T1
Pickering, TG1
Shimada, K1
Kario, K1
Hamada, N1
Nishi, Y1
Tajiri, Y1
Setoyama, K1
Kamimura, R1
Miyahara, K1
Nuruki, N1
Hosoda, H1
Kangawa, K1
Kojima, M1
Mifune, H1
Yildiz, A1
Hursit, M1
Celik, AV1
Kayacan, SM1
Yazici, H1
Akkaya, V1
Gürol, AO1
Karsidag, K1
Balabolkin, MI1
Khasanova, ER1
Trukhina, TV1
Kreminskaia, VM1
Courtney, CH1
McCance, DR1
Atkinson, AB1
Bassett, J1
Ennis, CN1
Sheridan, B1
Bell, PM1
Ueshiba, H1
Miyachi, Y1
Mediavilla García, JD1
Sabio, JM1
Fernández-Torres, C1
Aliaga Martínez, L1
Jiménez-Alonso, J1
Yilmaz, MI1
Sonmez, A1
Caglar, K1
Celik, T1
Yenicesu, M1
Eyileten, T1
Acikel, C1
Oguz, Y1
Yavuz, I1
Vural, A1
Moiseev, VS1
Ivleva, AIa1
Kobalava, ZhD1
Pool, JL1
Andersson, PE1
Lithell, H1
Jeng, JR1
Sheu, WH1
Jeng, CY1
Huang, SH1
Shieh, SM1
Zehetgruber, M1
Christ, G1
Gabriel, H1
Mundigler, G1
Beckmann, R1
Binder, BR1
Huber, K1
Lazebnik, LB1
Melichenko, SB1
Serebrov, AN1
Takahashi, A1
Kushiro, T1
Kanmatsuse, K1
Hirano, T1
Yoshino, G1
Kashiwazaki, K1
Adachi, M1
Khan, MA1
Morgan, RJ1
Mikhailidis, DP1
Huupponen, R1
Lehtonen, A1
Vähätalo, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level in Hypertensive Patients: Speckle Tracking Echocardiography[NCT03990480]Phase 4230 participants (Actual)Interventional2018-12-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

7 trials available for doxazosin and Insulin Sensitivity

ArticleYear
Adrenergic blockade improved insulin resistance in patients with morning hypertension: the Japan Morning Surge-1 Study.
    Journal of hypertension, 2009, Volume: 27, Issue:6

    Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Circ

2009
Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study.
    Clinical nephrology, 2002, Volume: 58, Issue:6

    Topics: Adult; Amlodipine; Antihypertensive Agents; Doxazosin; Female; Homeostasis; Humans; Insulin Resistan

2002
Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action.
    Metabolism: clinical and experimental, 2003, Volume: 52, Issue:9

    Topics: Acetylcholine; Adrenergic alpha-Antagonists; Adult; Aged; Blood Flow Velocity; Blood Glucose; Cross-

2003
Effect of doxazosin on insulin resistance in hypertensive patients with obesity.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2003, Volume: 35, Issue:9

    Topics: Adipose Tissue; Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Doxazosin; Female; Humans

2003
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
    Nephrology (Carlton, Vic.), 2007, Volume: 12, Issue:2

    Topics: Adiponectin; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers

2007
Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow.
    American journal of hypertension, 1996, Volume: 9, Issue:4 Pt 1

    Topics: Adult; Aged; Antihypertensive Agents; Body Mass Index; Double-Blind Method; Doxazosin; Enalapril; Fe

1996
[Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus].
    Terapevticheskii arkhiv, 1998, Volume: 70, Issue:2

    Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Doxazosin; Female; Hemodynamics; Humans; H

1998

Other Studies

11 other studies available for doxazosin and Insulin Sensitivity

ArticleYear
Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:6

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type

2012
[Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension].
    Terapevticheskii arkhiv, 2002, Volume: 74, Issue:12

    Topics: Adrenergic alpha-Antagonists; Adult; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucos

2002
[Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension].
    Medicina clinica, 2004, Sep-11, Volume: 123, Issue:8

    Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Catecholamines; Doxazosin; Drug Resistance; Fe

2004
[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 1995, Issue:5

    Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Doxazosin;

1995
Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient.
    British journal of clinical practice. Supplement, 1994, Volume: 74

    Topics: Coronary Disease; Doxazosin; Humans; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance

1994
Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance.
    American heart journal, 1996, Volume: 132, Issue:4

    Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Glucose; Case-Control Studies; Doxazosi

1996
Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters.
    Thrombosis and haemostasis, 1998, Volume: 79, Issue:2

    Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Doxazosin; Fibrinolysis; Humans; Hyperten

1998
[Effects of doxazosin and hydralazine on insulin sensitivity and sympathetic function in spontaneously hypertensive rat (SHR)].
    Nihon Jinzo Gakkai shi, 1998, Volume: 40, Issue:4

    Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Doxazosin; Hydralazine; Hypertension

1998
Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
    American journal of hypertension, 2001, Volume: 14, Issue:9 Pt 1

    Topics: Aged; Antihypertensive Agents; Apolipoproteins; Blood Glucose; Blood Pressure; C-Peptide; Cholestero

2001
The choice of antihypertensive drugs in patients with erectile dysfunction.
    Current medical research and opinion, 2002, Volume: 18, Issue:2

    Topics: Aged; Antihypertensive Agents; Diabetes Complications; Doxazosin; Erectile Dysfunction; Humans; Hype

2002
Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients.
    European journal of clinical pharmacology, 1992, Volume: 43, Issue:4

    Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Doxazosin; Female; Heart Rate; Human

1992
chemdatabank.com